IN2012DN03219A - - Google Patents
Info
- Publication number
- IN2012DN03219A IN2012DN03219A IN3219DEN2012A IN2012DN03219A IN 2012DN03219 A IN2012DN03219 A IN 2012DN03219A IN 3219DEN2012 A IN3219DEN2012 A IN 3219DEN2012A IN 2012DN03219 A IN2012DN03219 A IN 2012DN03219A
- Authority
- IN
- India
- Prior art keywords
- formulations
- stable
- hyaluronidase
- immunoglobulin
- months
- Prior art date
Links
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108010003272 Hyaluronate lyase Proteins 0.000 abstract 1
- 102000001974 Hyaluronidases Human genes 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960002773 hyaluronidase Drugs 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27704509P | 2009-09-17 | 2009-09-17 | |
PCT/US2010/002545 WO2011034604A2 (en) | 2009-09-17 | 2010-09-16 | Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN03219A true IN2012DN03219A (sl) | 2015-10-23 |
Family
ID=43034406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3219DEN2012 IN2012DN03219A (sl) | 2009-09-17 | 2010-09-16 |
Country Status (20)
Country | Link |
---|---|
US (1) | US9084743B2 (sl) |
EP (1) | EP2477603B1 (sl) |
JP (1) | JP5734985B2 (sl) |
KR (1) | KR101441768B1 (sl) |
CN (1) | CN102655853B (sl) |
AU (1) | AU2010296017C1 (sl) |
BR (1) | BR112012005890B1 (sl) |
CA (1) | CA2774053C (sl) |
CO (1) | CO6460736A2 (sl) |
DK (1) | DK2477603T3 (sl) |
EA (1) | EA026112B1 (sl) |
ES (1) | ES2578478T3 (sl) |
HK (1) | HK1173652A1 (sl) |
HR (1) | HRP20160530T1 (sl) |
HU (1) | HUE028832T2 (sl) |
IN (1) | IN2012DN03219A (sl) |
MX (1) | MX2012003282A (sl) |
PL (1) | PL2477603T3 (sl) |
PT (1) | PT2477603E (sl) |
WO (1) | WO2011034604A2 (sl) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2405015T3 (pl) | 2003-03-05 | 2016-09-30 | Rozpuszczalna glikoproteina o aktywności hialuronizady (sHASEGP), sposób jej wytwarzania, jej zastosowania i zawierające ją kompozycje farmaceutyczne | |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
WO2009111066A1 (en) | 2008-03-06 | 2009-09-11 | Halozyme, Inc. | Large-scale production of soluble hyaluronidase |
TWI532498B (zh) | 2008-03-17 | 2016-05-11 | 巴克斯特保健公司 | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
KR20160052812A (ko) | 2008-04-14 | 2016-05-12 | 할로자임, 아이엔씨 | 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도 |
WO2010034442A1 (en) * | 2008-09-23 | 2010-04-01 | F. Hoffmann-La Roche Ag | Purification of erythropoietin |
DK2477603T3 (en) | 2009-09-17 | 2016-06-13 | Baxalta Inc | STABLE CO-DEVELOPMENT OF hyaluronidase and Immunoglobulin, AND METHODS OF USE THEREOF |
AU2011212440B2 (en) | 2010-02-04 | 2015-01-22 | Csl Behring Ag | Immunoglobulin preparation |
US10420923B1 (en) | 2010-08-10 | 2019-09-24 | Amiram Katz | Method and device for intrathecal administering of immunoglobulin |
US9993529B2 (en) | 2011-06-17 | 2018-06-12 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
BR112013032396A2 (pt) | 2011-06-17 | 2016-11-22 | Halozyme Inc | formulações estáveis de aplicações relacionadas à enzima de degradação de ácido hialurônico |
EA030440B1 (ru) | 2011-10-24 | 2018-08-31 | Галозим, Инк. | Сопровождающая диагностика для терапии антигиалуронановым агентом и способы ее применения |
US9241869B2 (en) | 2011-10-25 | 2016-01-26 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
RS59703B1 (sr) | 2011-12-30 | 2020-01-31 | Halozyme Inc | Varijante ph20 polipeptida, njihove formulacije i upotrebe |
TWI719468B (zh) * | 2012-07-24 | 2021-02-21 | 日商日產化學股份有限公司 | 培養基組成物、其用途、細胞或組織之培養方法及細胞或組織培養物 |
US9664671B2 (en) | 2012-07-24 | 2017-05-30 | Nissan Chemical Industries, Ltd. | Culture medium composition and method of culturing cell or tissue using thereof |
US10017805B2 (en) | 2012-08-23 | 2018-07-10 | Nissan Chemical Industries, Ltd. | Enhancing ingredients for protein production from various cells |
CN112999245A (zh) * | 2012-09-26 | 2021-06-22 | 骨治疗公司 | 包含溶剂/去污剂处理过的血浆(s/d血浆)的制剂及其用途 |
KR101454646B1 (ko) * | 2012-11-05 | 2014-10-27 | (주)한국비엠아이 | 히알루로니다아제의 안정화 제제 및 이를 포함하는 액상제제 |
US9839579B2 (en) | 2013-04-24 | 2017-12-12 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9700485B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9707154B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9700486B2 (en) * | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9707155B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9603775B2 (en) | 2013-04-24 | 2017-03-28 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9717649B2 (en) | 2013-04-24 | 2017-08-01 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9707153B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9717648B2 (en) | 2013-04-24 | 2017-08-01 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9849066B2 (en) | 2013-04-24 | 2017-12-26 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9713572B2 (en) | 2013-04-24 | 2017-07-25 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
HUE044737T2 (hu) | 2013-05-06 | 2019-11-28 | Baxalta Inc | Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel |
ES2959451T3 (es) | 2013-09-11 | 2024-02-26 | Eagle Biologics Inc | Formulaciones proteicas líquidas que contienen organofosfatos |
US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
US20160074515A1 (en) | 2014-06-20 | 2016-03-17 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
CA2957820A1 (en) | 2014-08-22 | 2016-02-25 | Nectagen, Inc. | Affinity proteins and uses thereof |
ES2890669T3 (es) | 2014-09-09 | 2022-01-21 | Janssen Biotech Inc | Terapias de combinación con anticuerpos anti-CD38 |
KR102497368B1 (ko) | 2014-10-01 | 2023-02-10 | 이글 바이올로직스 인코포레이티드 | 점도-저하제를 함유하는 폴리삭카라이드 및 핵산 제형 |
KR102597989B1 (ko) | 2014-12-04 | 2023-11-02 | 얀센 바이오테크 인코포레이티드 | 급성 골수성 백혈병을 치료하기 위한 항-cd38 항체 |
US10766965B2 (en) * | 2015-05-20 | 2020-09-08 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
CR20170587A (es) | 2015-06-22 | 2018-04-03 | Janssen Biotech Inc | Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
WO2017079150A1 (en) | 2015-11-03 | 2017-05-11 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-cd38 antibodies and their uses |
CN109415714A (zh) * | 2016-04-29 | 2019-03-01 | 艾诺奥医药品有限公司 | 体内使用软骨素酶和/或透明质酸酶以增强药剂的递送 |
JP2019527678A (ja) * | 2016-06-28 | 2019-10-03 | ユーエムセー・ユトレヒト・ホールディング・ベー・フェー | CD38に特異的に結合する抗体によるIgE媒介疾患の治療 |
CA3060169A1 (en) * | 2017-04-21 | 2018-10-25 | Csl Behring Ag | Immunoglobulin products for use in the treatment of chronic inflammatory demyelinating polyneuropathy |
AU2018359527A1 (en) | 2017-10-31 | 2020-05-07 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
KR20200140799A (ko) * | 2018-01-31 | 2020-12-16 | 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 | 호흡기 세포융합 바이러스에 대하여 사용하기 위한 핵산 항체 작제물 |
JP7204729B2 (ja) * | 2018-07-25 | 2023-01-16 | アルテオゼン インコーポレイテッド | 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 |
JP2022516513A (ja) * | 2018-12-31 | 2022-02-28 | ラニ セラピューティクス, エルエルシー | 嚥下可能薬物送達デバイスを使用する腸管の管腔への送達のための治療剤調製物 |
CN110728044B (zh) * | 2019-09-30 | 2022-08-02 | 哈尔滨工程大学 | 一种针对于活塞环槽内气体压力状态的集成计算方法 |
KR102265730B1 (ko) * | 2020-11-06 | 2021-06-17 | 주식회사 본에스티스 | 피부 주름 개선 및 미백용 화장료 조성물 |
CA3228105A1 (en) * | 2021-08-02 | 2023-02-09 | argenx BV | Subcutaneous unit dosage forms |
AU2022347379A1 (en) * | 2021-09-14 | 2024-03-21 | Takeda Pharmaceutical Company Limited | Facilitated delivery of concentrated antibody formulations using hyaluronidase |
AU2022376750A1 (en) * | 2021-10-29 | 2024-05-16 | Alteogen Inc. | Pharmaceutical composition comprising human hyaluronidase ph20 and drug |
WO2023170680A1 (en) | 2022-03-08 | 2023-09-14 | Equashield Medical Ltd | Fluid transfer station in a robotic pharmaceutical preparation system |
CN115957332B (zh) * | 2022-11-01 | 2023-10-10 | 北京华睿鼎信科技有限公司 | 透明质酸酶稳定的布瑞诺龙纳米晶及其制备方法与应用 |
KR102554775B1 (ko) * | 2023-02-07 | 2023-07-12 | 한국코러스 주식회사 | 히알루로니다제의 안정화제 및 이를 포함하는 히알루로니다제 제형 |
Family Cites Families (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3966906A (en) | 1961-10-11 | 1976-06-29 | Behringwerke Aktiengesellschaft | Disaggregated gamma globulin and process for preparing it |
US3869436A (en) | 1971-06-01 | 1975-03-04 | Statens Bakteriologiska Lab | Method for fractionating plasma proteins using peg and ion-exchangers |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS5420124B2 (sl) | 1974-01-16 | 1979-07-20 | ||
CA1064396A (en) | 1975-02-18 | 1979-10-16 | Myer L. Coval | Fractional precipitation of gamma globulin with polyethylene glycol |
JPS5731623B2 (sl) | 1975-02-19 | 1982-07-06 | ||
US4126605A (en) | 1975-12-29 | 1978-11-21 | Plasmesco Ag | Process of improving the compatibility of gamma globulins |
US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
US4165370A (en) | 1976-05-21 | 1979-08-21 | Coval M L | Injectable gamma globulin |
US4124576A (en) | 1976-12-03 | 1978-11-07 | Coval M L | Method of producing intravenously injectable gamma globulin |
JPS5420124A (en) | 1977-07-14 | 1979-02-15 | Green Cross Corp:The | Preparation of gamma-globulin intravenous injection |
US4186192A (en) | 1978-12-18 | 1980-01-29 | Cutter Laboratories, Inc. | Stabilized immune serum globulin |
US4362661A (en) | 1979-08-09 | 1982-12-07 | Teijin Limited | Immunoglobulin composition having a high monomer content, and process for production thereof |
US4374763A (en) | 1979-09-17 | 1983-02-22 | Morishita Pharmaceutical Co., Ltd. | Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof |
JPS5731623A (en) | 1980-07-30 | 1982-02-20 | Morishita Seiyaku Kk | Production of gamma-globulin for intravenous injection |
JPS57128635A (en) | 1981-01-30 | 1982-08-10 | Morishita Seiyaku Kk | Pharmaceutical preparation of gamma-globulin for venoclysis |
US4499073A (en) | 1981-08-24 | 1985-02-12 | Cutter Laboratories, Inc. | Intravenously injectable immune serum globulin |
US4396608A (en) | 1981-08-24 | 1983-08-02 | Cutter Laboratories | Intravenously injectable immune serum globulin |
US4439421A (en) | 1982-08-30 | 1984-03-27 | Baxter Travenol Laboratories, Inc. | Stabilized gamma globulin concentrate |
DK166763B1 (da) | 1983-03-16 | 1993-07-12 | Immuno Ag | Immunoglobulin-g-holdig fraktion |
US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
JPH0669961B2 (ja) | 1984-09-25 | 1994-09-07 | 株式会社ミドリ十字 | 免疫グロブリンの加熱処理方法 |
US4597966A (en) | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
JPH0662436B2 (ja) | 1986-05-19 | 1994-08-17 | 株式会社ミドリ十字 | 静注用免疫グロブリン製剤の製造方法 |
JP2547556B2 (ja) | 1987-02-06 | 1996-10-23 | 株式会社 ミドリ十字 | r−グロブリンの液状製剤 |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
JP2871709B2 (ja) | 1988-11-21 | 1999-03-17 | 住友製薬株式会社 | 免疫グロブリンg結合活性を有する新規な蛋白質プロテインh、該蛋白質をコードする遺伝子及び該蛋白質の製造法 |
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
DE3921528A1 (de) | 1989-06-30 | 1991-01-10 | Draegerwerk Ag | Messzelle fuer den elektrochemischen gasnachweis |
US5177194A (en) | 1990-02-01 | 1993-01-05 | Baxter International, Inc. | Process for purifying immune serum globulins |
US5945098A (en) | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
US6552170B1 (en) * | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US5721348A (en) | 1990-12-14 | 1998-02-24 | University Of Connecticut | DNA encoding PH-20 proteins |
AT402261B (de) | 1991-01-25 | 1997-03-25 | Immuno Ag | Komplex enthaltend den gerinnungsfaktor ix |
JPH04346934A (ja) | 1991-05-24 | 1992-12-02 | Green Cross Corp:The | γ−グロブリンの液状製剤 |
CH684164A5 (de) | 1992-01-10 | 1994-07-29 | Rotkreuzstiftung Zentrallab | Intravenös anwendbare Immunglobulinlösung. |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
AU7097094A (en) | 1993-06-01 | 1994-12-20 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
FR2706466B1 (fr) | 1993-06-14 | 1995-08-25 | Aetsrn | Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré. |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
DE4344824C1 (de) | 1993-12-28 | 1995-08-31 | Immuno Ag | Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung |
US5795569A (en) | 1994-03-31 | 1998-08-18 | Amgen Inc. | Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation |
WO1995026746A1 (en) | 1994-03-31 | 1995-10-12 | Amgen Inc. | Compositions and methods for stimulating megakaryocyte growth and differentiation |
GB9418092D0 (en) | 1994-09-08 | 1994-10-26 | Red Cross Found Cent Lab Blood | Organic compounds |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5747027A (en) | 1995-04-07 | 1998-05-05 | The Regents Of The University Of California | BH55 hyaluronidase |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
US6828431B1 (en) | 1999-04-09 | 2004-12-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
US5958750A (en) | 1996-07-03 | 1999-09-28 | Inctye Pharmaceuticals, Inc. | Human hyaluronidase |
US5665069A (en) | 1996-07-19 | 1997-09-09 | Cumer; Patricia Lynn | Pressure-directed peribulbar anesthesia delivery device |
US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
US6193963B1 (en) | 1996-10-17 | 2001-02-27 | The Regents Of The University Of California | Method of treating tumor-bearing patients with human plasma hyaluronidase |
US6123938A (en) | 1996-10-17 | 2000-09-26 | The Regents Of The University Of California | Human urinary hyaluronidase |
US6258351B1 (en) | 1996-11-06 | 2001-07-10 | Shearwater Corporation | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
JP4270590B2 (ja) | 1997-03-19 | 2009-06-03 | 田辺三菱製薬株式会社 | 免疫グロブリン製剤 |
GB9705810D0 (en) * | 1997-03-20 | 1997-05-07 | Common Services Agency | Intravenous immune globulin |
US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
AT405739B (de) | 1997-09-19 | 1999-11-25 | Immuno Ag | Verfahren zur reinigung von antithrombin iii |
US6448369B1 (en) | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
ATE399809T1 (de) | 1998-03-12 | 2008-07-15 | Nektar Therapeutics Al Corp | Verfahren zur herstellung von polymerkonjugaten |
EP1095243A2 (en) | 1998-07-03 | 2001-05-02 | Neles Field Controls Oy | Method and arrangement for measuring fluid |
US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
PE20010288A1 (es) | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
US6461802B1 (en) | 1999-08-02 | 2002-10-08 | Agfa-Gevaert | Adhesive layer for polyester film |
DK1259562T3 (da) | 1999-12-22 | 2006-04-18 | Nektar Therapeutics Al Corp | Sterisk hindrede derivater af vandoplöselige polymerer |
US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
US20030212021A1 (en) * | 2001-01-25 | 2003-11-13 | Frost Gregory I. | Myeloid colony stimulating factor and uses thereof |
US6602498B2 (en) | 2000-02-22 | 2003-08-05 | Shearwater Corporation | N-maleimidyl polymer derivatives |
US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
DE60129432T2 (de) | 2000-05-16 | 2008-04-17 | Bolder Biotechnology, Inc., Louisville | Verfahren zur rückfaltung von proteinen mit freien cysteinresten |
WO2002049673A2 (en) | 2000-12-20 | 2002-06-27 | F. Hoffmann-La Roche Ag | Conjugates of erythropoietin (pep) with polyethylene glycol (peg) |
ES2184594B1 (es) | 2001-01-17 | 2004-01-01 | Probitas Pharma Sa | Procedimiento para la produccion de gammaglobulina g humana inactivada de virus. |
US6571605B2 (en) | 2001-01-19 | 2003-06-03 | Larry Keith Johnson | Constant-head soil permeameter for determining the hydraulic conductivity of earthen materials |
TWI246524B (en) | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
AU2002352524B2 (en) | 2001-11-07 | 2007-10-04 | Nektar Therapeutics | Branched polymers and their conjugates |
AU2002351197A1 (en) | 2001-11-28 | 2003-06-10 | Neose Technologies, Inc. | Glycopeptide remodeling using amidases |
US7192468B2 (en) | 2002-04-15 | 2007-03-20 | Fluor Technologies Corporation | Configurations and method for improved gas removal |
JP2004147535A (ja) | 2002-10-29 | 2004-05-27 | Japan Science & Technology Agency | ギラン・バレー症候群及び/又はフィッシャー症候群発症モデル非ヒト動物 |
KR20040040782A (ko) | 2002-11-08 | 2004-05-13 | 선바이오(주) | 신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법 |
EP2298874A1 (en) | 2002-12-16 | 2011-03-23 | Halozyme, Inc. | Human chondroitinase glycoprotein (CHASEGP), process for preparing the same, and pharmaceutical compositions comprising thereof |
RS51318B (sr) | 2002-12-16 | 2010-12-31 | Genentech Inc. | Varijante imunoglobulina i njihova upotreba |
JP2004238392A (ja) | 2003-01-14 | 2004-08-26 | Nipro Corp | 安定化された蛋白質性製剤 |
TR201808801T4 (tr) * | 2003-02-10 | 2018-07-23 | Biogen Ma Inc | İmmünoglobulin formülasyonu ve bunun hazırlanış yöntemi. |
ES2911435T3 (es) | 2003-02-26 | 2022-05-19 | Nektar Therapeutics | Conjugados de polímero-resto de Factor VIII |
PL2405015T3 (pl) * | 2003-03-05 | 2016-09-30 | Rozpuszczalna glikoproteina o aktywności hialuronizady (sHASEGP), sposób jej wytwarzania, jej zastosowania i zawierające ją kompozycje farmaceutyczne | |
US20090123367A1 (en) | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
US7871607B2 (en) * | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
JP4346934B2 (ja) | 2003-03-25 | 2009-10-21 | 日本碍子株式会社 | セラミックス構造体の製造方法 |
US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
KR100512483B1 (ko) | 2003-05-07 | 2005-09-05 | 선바이오(주) | 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법 |
CA2510040C (en) | 2003-05-23 | 2012-01-03 | Nektar Therapeutics Al, Corporation | Polymeric reagents and polymer-biomolecule conjugates comprising carbamate linkages |
EP1532983A1 (en) | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
US7572613B2 (en) * | 2004-06-25 | 2009-08-11 | Klein Jeffrey A | Drug delivery system for accelerated subcutaneous absorption |
EP3339445B1 (en) * | 2006-09-08 | 2020-07-15 | AbbVie Bahamas Ltd. | Interleukin -13 binding proteins |
RU2471867C2 (ru) * | 2007-06-19 | 2013-01-10 | Тамара П. Уваркина | Гиалуронидаза и способ ее применения |
WO2009111066A1 (en) | 2008-03-06 | 2009-09-11 | Halozyme, Inc. | Large-scale production of soluble hyaluronidase |
TWI532498B (zh) | 2008-03-17 | 2016-05-11 | 巴克斯特保健公司 | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
KR20160052812A (ko) * | 2008-04-14 | 2016-05-12 | 할로자임, 아이엔씨 | 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도 |
US20090311237A1 (en) | 2008-04-14 | 2009-12-17 | Frost Gregory I | Combination therapy using a soluble hyaluronidase and a bisphosphonate |
TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
EA036569B1 (ru) | 2008-12-09 | 2020-11-24 | Галозим, Инк. | Способ получения полипептида гиалуронидазы ph20 |
MY157239A (en) | 2009-05-27 | 2016-05-13 | Baxalta Inc | A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use |
DK2477603T3 (en) | 2009-09-17 | 2016-06-13 | Baxalta Inc | STABLE CO-DEVELOPMENT OF hyaluronidase and Immunoglobulin, AND METHODS OF USE THEREOF |
AU2010202125B1 (en) * | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
US8796430B2 (en) * | 2010-05-26 | 2014-08-05 | Baxter International Inc. | Method to produce an immunoglobulin preparation with improved yield |
EP2595624B1 (en) * | 2010-07-20 | 2018-01-31 | Halozyme, Inc. | Methods of treatment or prevention of the adverse side-effects associated with administration of an anti-hyaluronan agent |
AR083034A1 (es) * | 2010-09-17 | 2013-01-30 | Baxter Int | ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO |
ES2634669T3 (es) | 2011-02-08 | 2017-09-28 | Halozyme, Inc. | Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata |
US9993529B2 (en) | 2011-06-17 | 2018-06-12 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
RS59703B1 (sr) | 2011-12-30 | 2020-01-31 | Halozyme Inc | Varijante ph20 polipeptida, njihove formulacije i upotrebe |
CA2986512C (en) | 2012-04-04 | 2022-05-17 | Halozyme, Inc. | Combination therapy with an anti-hyaluronan agent and a tumor-targeted taxane |
-
2010
- 2010-09-16 DK DK10760140.3T patent/DK2477603T3/en active
- 2010-09-16 CA CA2774053A patent/CA2774053C/en active Active
- 2010-09-16 HU HUE10760140A patent/HUE028832T2/en unknown
- 2010-09-16 KR KR1020127009795A patent/KR101441768B1/ko active IP Right Grant
- 2010-09-16 PL PL10760140.3T patent/PL2477603T3/pl unknown
- 2010-09-16 EA EA201200490A patent/EA026112B1/ru unknown
- 2010-09-16 WO PCT/US2010/002545 patent/WO2011034604A2/en active Application Filing
- 2010-09-16 CN CN201080051813.3A patent/CN102655853B/zh active Active
- 2010-09-16 JP JP2012529751A patent/JP5734985B2/ja active Active
- 2010-09-16 US US12/807,991 patent/US9084743B2/en active Active
- 2010-09-16 BR BR112012005890-8A patent/BR112012005890B1/pt not_active IP Right Cessation
- 2010-09-16 EP EP10760140.3A patent/EP2477603B1/en active Active
- 2010-09-16 MX MX2012003282A patent/MX2012003282A/es active IP Right Grant
- 2010-09-16 ES ES10760140.3T patent/ES2578478T3/es active Active
- 2010-09-16 IN IN3219DEN2012 patent/IN2012DN03219A/en unknown
- 2010-09-16 AU AU2010296017A patent/AU2010296017C1/en active Active
- 2010-09-16 PT PT107601403T patent/PT2477603E/pt unknown
-
2012
- 2012-04-12 CO CO12060153A patent/CO6460736A2/es unknown
-
2013
- 2013-01-15 HK HK13100640.9A patent/HK1173652A1/zh not_active IP Right Cessation
-
2016
- 2016-05-18 HR HRP20160530TT patent/HRP20160530T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
BR112012005890A2 (pt) | 2019-09-24 |
EA026112B1 (ru) | 2017-03-31 |
US9084743B2 (en) | 2015-07-21 |
CN102655853A (zh) | 2012-09-05 |
JP5734985B2 (ja) | 2015-06-17 |
JP2013505237A (ja) | 2013-02-14 |
EA201200490A1 (ru) | 2012-12-28 |
HK1173652A1 (zh) | 2013-05-24 |
WO2011034604A9 (en) | 2012-01-19 |
EP2477603B1 (en) | 2016-03-30 |
ES2578478T3 (es) | 2016-07-27 |
HUE028832T2 (en) | 2017-01-30 |
WO2011034604A3 (en) | 2011-12-01 |
WO2011034604A2 (en) | 2011-03-24 |
US20110066111A1 (en) | 2011-03-17 |
PL2477603T3 (pl) | 2016-10-31 |
HRP20160530T1 (hr) | 2016-07-29 |
CA2774053C (en) | 2015-04-28 |
MX2012003282A (es) | 2012-04-30 |
BR112012005890B1 (pt) | 2023-01-17 |
KR101441768B1 (ko) | 2014-09-17 |
CN102655853B (zh) | 2015-07-29 |
CO6460736A2 (es) | 2012-06-15 |
PT2477603E (pt) | 2016-06-16 |
AU2010296017C1 (en) | 2013-09-19 |
AU2010296017A1 (en) | 2012-05-03 |
EP2477603A2 (en) | 2012-07-25 |
AU2010296017B2 (en) | 2013-06-06 |
DK2477603T3 (en) | 2016-06-13 |
KR20120105426A (ko) | 2012-09-25 |
CA2774053A1 (en) | 2011-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN03219A (sl) | ||
MX2019008428A (es) | Inhibidores de glucosilceramida sintasa. | |
BR112014030682A2 (pt) | diferenciação de células tronco embrionárias humanas em células pancreáticas endócrinas | |
EP2603227A4 (en) | IMPROVED HEMATOPOETIC TRIBE AND PRECURSOR CELL THERAPY | |
BR112014031874A2 (pt) | método para preparar células-tronco em concentração elevada | |
MX2016013635A (es) | Métodos para aumentar los niveles de eritrocitos y tratar de la enfermedad de células falciformes. | |
NZ706296A (en) | Glucosylceramide synthase inhibitors | |
MX2011010930A (es) | Modulacion de respuestas inflamatorias a través de factor xi. | |
GB0920703D0 (en) | Compositions containing satiogens and methods of use | |
IN2015KN00005A (sl) | ||
MX2019000547A (es) | Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas. | |
MX2015016387A (es) | Composicion hemostatica degradable. | |
IN2014DN07483A (sl) | ||
MX2015007584A (es) | Triheptanoina para el tratamiento de la deficiencia del transportador de glucosa 1. | |
SG10201804952QA (en) | Glucosylceramide synthase inhibitors | |
MX2022008842A (es) | Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial. | |
MX2015016381A (es) | Composicion hemostatica degradable. | |
BR112013028257A2 (pt) | "composição de fármaco biológico, métodos de manipulação de uma composição de fármaco biológica com células vivas e de fornecer composições de células vivas em um ponto de instalação de tratamento, bem como uso de células vivas formuladas em tampão não nutritivo" | |
PH12014500859A1 (en) | Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof | |
BR112015022196A2 (pt) | composições de liberação prolongada, que compreendem hidrocodona e acetaminofeno para rápido início e analgesia prolongada, que podem ser administradas independentemente de alimentos | |
MX365464B (es) | Prodecimiento para preparar inhibidores de la glucosilceramida sintasa. | |
MX2015015200A (es) | Inhibidores de nicotamida fosforibosiltransferasa, composiciones, productos y usos de los mismos. | |
MD545Y (en) | Process for treating tomato seeds with low viability | |
IN2013MU02370A (sl) | ||
Mastgutov et al. | Correction of the face soft tissue defect using autologous fat tissue enriched by cells of stromal-vascular fraction |